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Abstract
Background: Antimicrobial resistance is one of the most challenging issues in modern medicine.
Methods: We evaluated the secular trends of the relative frequency of blood isolates and of the pattern of their
in vitro antimicrobial susceptibility in our hospital during the last four and a half years.
Results: Overall, the data regarding the relative frequency of blood isolates in our newly founded hospital do not
differ significantly from those of hospitals that are functioning for a much longer period of time. A noteworthy
emerging problem is the increasing antimicrobial resistance of Gram-negative bacteria, mainly Acinetobacter
baumannii and Klebsiella pneumoniae to various classes of antibiotics. Acinetobacter baumannii isolates showed an
increase of resistance to amikacin (p = 0.019), ciprofloxacin (p = 0.001), imipenem (p < 0.001), and piperacillin/
tazobactam (p = 0.01) between the first and second period of the study.
Conclusion: An alarming increase of the antimicrobial resistance of Acinetobacter baumannii isolates has been
noted during our study.
Background
Increasing antimicrobial resistance among bloodstream
isolates is considered a significant problem worldwide
[1,2]. This is especially true in some areas including the
countries of Southern Europe where a considerable pro-
portion of pathogens are resistant to antibiotics of several
classes [3]. Although antimicrobial resistance is noted in
all pathogens, some phenotypes of resistance such as
methicillin resistant Staphylococcus aureus (MRSA), vanco-
mycin resistant enterococci (VRE), methicillin resistant
coagulase negative staphylococci (MRCNS), and carbap-
enem resistant enterobacteriacae, Pseudomonas aeruginosa,
and Acinetobacter baumannii are of particular concern. We
sought to study the secular trends of the relative frequency
and antimicrobial resistance of blood isolates in a newly
founded hospital in Greece.
Methods
Patient population
The patient population comprised of patients admitted to
Henry Dunant Hospital, Athens, Greece in the period of
01/01/2001–30/06/2005. Henry Dunant Hospital was
founded in October 2000. It is a general tertiary hospital
with 450 beds covering most medical specialties with the
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exception of pediatrics, obstetrics, and transplant surgery.
It has 3 combined medical and surgical intensive care
units with a total of 38 beds.
Microbiological studies
Identification of the microorganisms to the species level
was performed with the automated system Vitek 2
(Biomérieux) according to the manufacturer's instruc-
tions. Not all, but only the first blood isolate per patient
was included in the study. The Bactec system (Becton-
Dickinson) was used during 2001, 2002, and 2003, and
the BacT Alert 3D (Biomérieux) was used during 2004 and
2005. Isolation of bacteria was followed by susceptibility
testing that was performed with the Vitek 2 system, apply-
ing the criteria suggested by the Clinical and Laboratory
Standards Institute (CLSI) [4,5]. The identification and
antimicrobial susceptibility of viridans Streptococci was
preformed by the use of API (BioMérieux) and the use of
the Kirby-Bauer method. Fungi were identified with the
use of the specific card for the Vitek 2 system. Susceptibil-
ity to colistin was tested by the Vitek method and the E-
test. Pulsed field gel electrophoresis and ribotyping were
not performed to exclude secondary outbreak strains.
Statistical analysis
Differences in proportions were compared by x2 test or
Fisher's exact test where appropriate. Statistical signifi-
cance was set for p < 0.05. All statistical analyses were per-
formed using SPSS 11.0 and S-PLUS 6.1 Professional.
Results
The frequency of isolation of bacteria from cultures of
blood specimens was 182 per 12,593 admissions during
2001 (14.4 per 1,000 admissions), 507 per 25,865 admis-
sions during 2002 (19.6 per 1,000 admissions), 693 per
30,597 admissions during 2003 (22.6 per 1,000 admis-
sions), 566 per 30,599 admissions during 2004 (18.4 per
1,000 admissions) and 208 per 15,683 admissions during
2005 (13.2 per 1,000 admissions). There was a significant
difference in the proportion of isolates identified over the
5year period (p < 0.001). The percentage of positive blood
cultures to the total number of blood cultures was 4.84%
for the year 2001, 6.46% for 2002, 7.91% for 2003, 6.71%
for 2004 and 5.7% for 2005. Regarding the relative fre-
quency of the bacteria isolated from blood specimens,
Gram-positive bacteria were more common than Gram-
negative bacteria throughout the study period (Table 1).
Coagulase negative staphylococci were the commonest
blood isolates (52.5 % of total). The relative frequency of
other Gram-positive and Gram-negative microorganisms
was the following, in descending order: Escherichia coli
(8.9 %), Staphylococcus aureus (5.9 %), Pseudomonas aeru-
ginosa (5.2 %), Klebsiella spp (4.8 %), Acinetobacter bau-
mannii  (4.1 %), Enterococcus faecalis (2.2 %), and
Enterococcus faecium (1.8 %). In Table 2 we summarized
the relative frequency of blood isolates by service, namely
wards and intensive care unit.
We compared the antimicrobial resistance of blood iso-
lates of two periods: the first period was 1/1/2002–31/12/
2003 and the second period 1/1/2004–30/6/2005. The
year 2001 was not included in the comparison of the anti-
microbial resistance because the in vitro susceptibility
data were not readily available. The antimicrobial resist-
ance of Gram-negative bacteria isolated from blood in our
hospital showed some interesting trends (Table 3). In
Table 4 we present data regarding the in vitro susceptibil-
ity patterns and the respective MIC90 of the isolated bacte-
ria. Acinetobacter baumannii isolates showed an increase of
resistance to amikacin (p = 0.019), ciprofloxacin (p =
0.001), imipenem (p < 0.001), and piperacillin/tazo-
bactam(p = 0.01) between the first and second period of
the study. In addition, we noted the appearance of resist-
ance to polymyxins in one Acinetobacter baumannii isolate.
Regarding the secular changes of the antimicrobial resist-
ance of Pseudomonas aeruginosa isolates during our study,
there was only one statistically significant association,
namely increased resistance to ceftazidime (p = 0.016).
The antimicrobial susceptibility pattern of Klebsiella pneu-
moniae  isolates changed significantly during our study.
Increased resistance of Klebsiella pneumoniae isolates was
noted for all beta lactams tested [specifically to piperacil-
lin/tazobactam (p < 0.001), ceftazidime (p = 0.01),
cefepime (p < 0.001), cefoxitin (p < 0.001) and mero-
penem (p < 0.001)] between the first and second period
of the study. There was also increased resistance of Kleb-
siella pneumoniae to ciprofloxacin (p = 0.006) and
tobramycin (p < 0.001).
Regarding the antimicrobial susceptibility pattern of
Gram-positive bacteria during our study there was a con-
siderable proportion of staphylococci with resistance
against oxacillin (Table 1); however, the difference of the
proportions of oxacillin resistant staphylococci between
the two study periods was not statistically significant
(Table 2). We did not isolate any staphylococci with resist-
ance to vancomycin. Enterococcus faecalis and Enterococcus
faecium  were generally susceptible to vancomycin
although some strains were resistant; however the differ-
ence of the proportions of VRE between the two study
periods was not statistically significant (Table 2).
Discussion
Patients with bacteremia have remained a challenge to
treat. Knowledge of the hospital epidemiology and anti-
microbial susceptibility pattern of blood isolates helps
physicians to effectively manage blood stream infections.
This is because considerable differences of the frequencyBMC Infectious Diseases 2006, 6:99 http://www.biomedcentral.com/1471-2334/6/99
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of blood isolates are reported even from hospitals of sim-
ilar size and mixture of patients of the same country [6].
In this study we evaluated the secular trends of the relative
frequency and antimicrobial resistance of blood isolates
in a newly founded Greek hospital. Gram-positive micro-
organisms are the most common blood isolates. Among
them, coagulase negative staphylococci are the common-
est blood isolates. The percentage of coagulase negative
staphylococci (%) is higher in our study than that
reported in large series (31.6%) [7-9]. It is possible that
the proportion of coagulase negative staphylococci that
were contaminants was considerable in our study. The
interpretation of blood cultures that are positive for coag-
ulase negative staphylococci has inherent difficulties and
requires careful reasoning [10]. The observed relative fre-
quency of MRSA was considerable high during the studied
period. Data from the WHONET Greece (antimicrobial
surveillance system) regarding the period from January
2005 through June 2005 showed that a significant propor-
tion of S. aureus blood isolates are resistant to methicillin
(MRSA strains). Specifically, 32.6%, 55.6%, and 69% of S.
aureus blood isolates from medical wards, surgical wards,
and ICUs respectively were MRSA.
In general, our results about the relative frequency of
blood isolates in our newly founded hospital are not sub-
stantially different from those of hospitals that are func-
tioning for a much longer period of time. Similar data
have been reported in studies performed in hospitals else-
where in Europe as well as in North America [7-9]. An
explanation may be that it is not the microbial ecology of
the structure (our newly founded tertiary urban hospital
compared to hospitals that are functioning for longer
time) but rather the characteristics of the admitted
patients like comorbidity, medications, and other host
factors that play the most important role in the relative
frequency of blood isolates.
It is also noteworthy that the isolation of Candida spp
from the blood was not uncommon during the study
period. This is in agreement with the reports from all over
the world regarding a considerable prevalence of fun-
gemia due to extensive use of antibiotics, aggressive treat-
ment of neoplastic disease, an expanding population of
patients with AIDS with prolonged survivors, use of ind-
welling devices for ICU monitoring, and many other fac-
tors that predispose to fungal infections [8,9]. Although
our hospital does not have a transplant unit, the observed
Table 1: Relative frequency of blood isolates in Henry Dunant Hospital, Athens, Greece (01/01/2001–30/6/2005).
Number of isolates (proportion within the year)
Microorganism
s
2001 (n = 182) 2002 (n = 506) 2003 (n = 693) 2004 (n = 566) 2005* (n = 
208)
Total p-value
Gram-positive
Coagulase-
negative 
staphylococci
84 (46.2) 282 (55.6) 377 (54.4) 297 (52.5) 94 (45.1) 1134 (52.5) 0.03
Staphylococcus 
aureus
12 (6.6) 40 (7.9) 42 (6.1) 27 (4.8) 8 (3.8) 129 (5.9) 0.16
Enterococcus 
faecalis
2 (1.1) 15 (3.0) 21 (3.0) 6 (1.1) 4 (1.9) 48 (2.2) 0.09
Enterococcus 
faecium
4 (2.2) 14 (2.8) 8 (1.2) 11 (1.9) 2 (0.9) 39 (1.8) 0.25
Gram negative
Escherichia coli 15 (8.2) 36 (7.1) 57 (8.2) 54 (9.5) 30 (14.4) 192 (8.9) 0.03
Pseudomonas 
aeruginosa
13 (7.1) 29 (5.7) 35 (5.0) 26 (4.6) 11 (5.3) 114 (5.2) 0.72
Acinetobacter 
baumannii
10 (5.5) 10 (2.0) 15 (2.2) 38 (6.7) 17 (8.2) 90 (4.1) <0.001
Proteus 
mirabilis
3 (1.7) 1 (0.2) 1 (0.1) 4 (0.7) 3 (1.4) 12 (0.5) 0.03
Klebsiella spp. 5 (2.8) 17 (3.4) 39 (5.6) 33 (5.7) 11 (5.3) 105 (4.8) 0.18
Enterobacter 
spp.
4 (2.2) 8 (1.6) 24 (3.5) 9 (1.6) 3 (1.4) 48 (2.2) 0.11
Salmonella spp. 2 (1.1) 1 (0.2) 4 (0.6) 9 (1.6) 0 (0) 16 (0.7) 0.05
Others (include 
other Gram 
positive and 
Gram negative)
22 (12) 25 (4.9) 34 (4.9) 26 (4.6) 15 (7.2) 122 (5.6) 0.002
Fungi
Candida 6 (3.3) 29 (5.7) 36 (5.2) 26 (4.6) 10 (4.8) 107 (4.9) 0.74BMC Infectious Diseases 2006, 6:99 http://www.biomedcentral.com/1471-2334/6/99
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high frequency of Candida isolates is probably explained
by the fact that oncology patients and thus neutropenic
patients constitute a significant portion of our patients.
We also evaluated in our study the trends of the antimi-
crobial resistance of the blood bacteria isolates in our
newly founded hospital. The antimicrobial resistance of
Acinetobacter baumannii showed an alarming increase dur-
ing the study. Acinetobacter baumannii remained suscepti-
ble to colistin during the two periods, although the
recovery of one resistant strain is of note [11,12]. Unfor-
tunately, antimicrobial resistance increased also for Kleb-
siella pneumoniae for all of the 7 antibiotics it was tested
for. These results are in concordance with data of the liter-
ature about the increasing antimicrobial resistance of
Gram-negative bacteria [13-15]. In addition, it is notewor-
thy that the majority of bloodstream K. pneumoniae strains
recovered in 2005 were resistant to meropenem, however
this would probably reflect a nosocomial outbreak of a
carbapenem-resistant K. pneumoniae clone.
We should acknowledge several limitations of our study.
First, the results obtained from the Vitek II were con-
firmed by the E-test methodology only for colistin. Sec-
ond, we did not proceed to the interpretation of the
results of this study in terms of culture contamination or
clinically relevant bloodstream infection. Third, pulsed-
field gel electrophoresis was not performed to identify
epidemic clones. Since molecular typing was not per-
formed some of the studied isolates with antimicrobial
resistance may be clonally related. Fourth, the number of
patients visit the outpatient clinic of the hospital was not
readily available. However, the number of positive blood
cultures in the ambulatory outpatients is relatively small
[16].
Conclusion
Our data suggest that the relative frequency and the anti-
microbial resistance pattern of the blood isolates in a
newly founded hospital is not very different from those
data described in the literature from other older hospitals
around the world. In addition, an alarming increase of
antimicrobial resistance was noted during our study for
Gram-negative bacteria, especially Acinetobacter baumannii
and Klebsiella pneumoniae.
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Number of isolates by service/total number of same species isolates within the year
Microorgani
sms
2002 2003 2004 2005*
Gram-
positive
Wards ICU Wards ICU Wards ICU Wards ICU
Coagulase-
negative 
staphylococci
158/282 124/282 191/377 186/377 159/297 138/297 49/94 45/94
Staphylococc
us aureus
26/40 14/40 21/42 21/42 17/27 10/27 6/8 2/8
Enterococcus 
faecalis
10/15 5/15 13/21 8/21 3/6 3/6 3/4 1/4
Enterococcus 
faecium
10/14 4/14 6//8 2/8 8/11 3/11 2/2 0/2
Gram 
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Escherichia 
coli
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Pseudomonas 
aeruginosa
17/29 12/29 18/35 17/35 14/26 12/26 6/11 5/11
Acinetobacte
r baumannii
2/10 8/10 7/15 8/15 9/38 29/38 7/17 10/17
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Table 3: Trends of antimicrobial resistance of Gram-positive and Gram-negative bacteria.
Number of resistant isolates/total isolates tested (proportion) within the year
Microorganism
s
2002 2003 2004 2 005 2002/2003 2004/2005 p-value**
Gram-positive
Staphylococcu
s epidermidis
Oxacillin 171/202 (84.7) 215/261 (82.4) 179/219 (81.2) 75/94 (79.8) 386/463 (83.3%) 254/313 (81.2%) 0.10
Gentamicin 144/202 (71.3) 168/261 (64.4) 148/219 (67.6) 54/94 (57.5) 312/463 (67.4%) 202/313 (64.5%) 0.37
Vancomycin 0/202 (0) 0/261 (0) 0/219 (0) 0/94 (0) 0/463 (0%) 0/313 (0%) NA
Staphylococcu
s aureus
Oxacillin 25/38 (65.8) 21/30 (70) 12/25 (48) 6/8 (75) 46/68 (67.6%) 18/33 (54.5%) 0.19
Gentamicin 23/38 (60.5) 4/30 (13.3) 6/25(24) 3/8 (37.5) 27/68 (39.7%) 9/33 (27.3%) 0.22
Vancomycin 0/38 (0) 0/30 (0) 0/25 (0) 0/8 (0) 0/68 (0%) 0/33 (0%) 1
Enterococcus 
faecalis
Vancomycin 0/14 (0) 2/19 (10.5) 0/7 (0) 0/4 (0) 2/33 (6.1%) 0/11 (0%) 1
Enterococcus 
faecium
Vancomycin 1/15 (6.7) 0/8 (0) 3/11 (27.3) 0/2 (0) 1/22 (4.5%) 3/13 (23.1%) 0.13
Gram negative
Acinetobacter 
baumannii
Amikacin 6/9 (66.6) 10/15 (66.6) 32/35 (91.4) 15/17 (88.2) 16/24 (66.7%) 47/52 (90.4%) 0.019
Ceftazidime 8/9 (88.8) 13/15 (86.6) 34/35 (97.1) 17/17 (100) 21/24 (87.5%) 51/52 (98.1%) 0.09
Ciprofloxacin 6/9 (66.6) 11/15 (73.3) 34/35 (97.1) 17/17 (100) 17/24 (70.8%) 51/52 (98.1%) 0.001
Colistin 1/9 (11.1) 0/15 (0) 0/35 (0) 1/17 (5.8) 0/24 (0%) 1/52 (0%) 1
Gentamicin 4/9 (44.4) 10/15 (66.6) 16/35 (45.7) 12/17 (70.5) 14/24 (58.3%) 28/52 (53.8%) 0.71
Imipenem 4/9 (44.4) 8/15 (53.3) 34/35 (97.1) 17/17 (100) 12/24 (50%) 51/52 (98.1%) <0.001
Piperacillin/
Tazobactam
7/9 (77.7) 12/15 (80) 34/35 (97.1) 17/17 (100) 19/24 (79.2%) 51/52 (98.1%) 0.01
Pseudomonas 
aeruginosa
Amikacin 15/32 (46.9) 15/33 (45.5) 17/25 (68) 4/11 (36.4) 30/65 (46.2%) 21/36 (58.3%) 0.24
Ceftazidime 18/32 (56.3) 19/33 (57.6) 21/25 (84) 8/11 (72.7) 37/65 (56.9%) 29/36 (80.6%) 0.016
Ciprofloxacin 20/32 (62.5) 14/33 (42.4) 17/25 (68) 5/11 (45.4) 34/65 (52.3%) 22/36 (61.1%) 0.39
Colistin 0/32 (0) 0/33 (0) 0/25 (0) 0/11 (0) 0/65 (0%) 0/36 (0%) 1
Imipenem 20/32 (62.5) 14/33 (42.4) 15/25 (60) 5/11 (45.4) 34/65 (52.3%) 20/36 (55.5%) 0.75
Piperacillin/
Tazobactam
3/32 (9.4) 7/33 (21.2) 18/25 (72) 2/11 (18.2) 10/65 (15.4%) 20/36 (55.5%) 0.10
Klebsiella 
pneumoniae
Ceftazidime 2/7 (28.6) 11/34 (32.4) 15/29 (51.7) 9/11 (81.8) 13/41 (31.7%) 24/40 (60%) 0.010
Ciprofloxacin 1/7 (14.3) 12/34 (35.3) 16/29 (55.2) 4/11 (36.4) 13/41 (31.7%) 20/40 (50%) 0.006
Meropenem 0/7 (0) 1/34 (2.9) 8/29 (27.6) 9/11 (81.8) 1/41 (2.4%) 17/40 (42.5%) <0.001
Cefepime 0/7 (0) 11/34 (32.4) 15/29 (51.7) 9/11 (81.8) 11/41 (26.8%) 24/40 (60%) <0.001
Cefoxitin 0/7 (0) 10/34 (29.4) 18/29 (62.1) 9/11 (81.8) 10/41 (24.4%) 27/40 (67.5%) <0.001
Tobramycin 0/7 (0) 8/34 (23.5) 17/29 (58.6) 9/11 (81.8) 8/41 (19.5%) 26/40 (65%) <0.001
Piperacillin/
Tazobactam
0/7 (0) 8/34 (23.5) 15/29 (51.7) 9/11 (81.8) 8/41 (19.5%) 24/40 (60%) <0.001
Escherichia 
coli
Amikacin 0/35 (0) 0/57 (0) 4/47(8.5) 1/30(0) 0/92 (0%) 5/77 (6.5%) 0.05
Ciprofloxacin 7/35 (0.2) 3/57 (5.2) 4/47(8.5) 9/30(30) 10/92 (10.9%) 13/77 (16.9%) 0.006
Piperacillin/
Tazobactam
1/35 (2.8) 1/57 (1.7) 4/47(8.5) 2/30(6.6) 2/92 (2.2%) 6/77 (7.8%) 0.37
Ceftazidime 2/35 (5.7) 0/57 (0) 4/47(8.5) 5/30(16.6) 2/92 (2.2%) 9/77 (11.7%) 0.02
Cefoxitin 4/35 (11.4) 1/57 (1.7) 4/47(8.5) 4/30(13.3) 5/92 (5.4%) 8/77 (10.4%) 0.18
Meropenem 1/35 (2.8) 0/57 (0) 1/47(2.1) 0/30(0) 1/92 (1.1%) 1/77 (1.3%) 0.52
* Data for the year 2005 refer to the period from January 2005 through June 2005.
** P-values refer to the comparison of proportions between 2002/2003 and 2004/2005.BMC Infectious Diseases 2006, 6:99 http://www.biomedcentral.com/1471-2334/6/99
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Table 4: Data on antimicrobial resistance patterns and respective MIC90 of isolated bacteria.
2002 2003 2004 2005
Microorganis
ms
S* I** R*** MIC9
0
#
SIR M I C 9
0
SIR M I C 9
0
SIR M I C 9
0
Gram-positive
Staphylococc
us epidermidis
Oxacillin 31/
202
0/202 171/
202
44 6 /
261
0/261 215/
261
43 6 /
214
0/214 179/
214
4 15/94 0/94 75/94 4
Gentamicin 58/
202
18/
202
126/
202
16 87/
261
20/
261
154/
261
16 71/
219
0/219 148/
219
16 40/94 10/94 44/94 16
Vancomycin 202/
202
0/202 0/202 2 261/
261
0/261 0/261 2 219/
219
0/219 0/219 2 94/94 0/94 0/94 4
Staphylococc
us aureus
Oxacillin 13/38 0/38 25/38 4 9/30 0/30 21/30 4 13/25 0/25 12/25 4 2/8 0/8 6/8 4
Gentamicin 16/38 13/38 9/38 8 21/30 5/30 4/30 8 19/25 0/25 6/25 4 5/8 1/8 2/8 0.5
Vancomycin 38/38 0/38 0/38 1 30/30 0/30 0/30 2 25/25 0/25 0/25 1 8/8 0/8 0/8 1
Enterococcus 
faecalis
Vancomycin 14/14 0/14 0/14 2 17/19 0/19 2/19 2 6/6 0/6 0/6 2 4/4 0/4 0/4 2
Enterococcus 
faecium
Vancomycin 13/14 0/14 1/14 1 8/8 0/8 0/8 1 2/2 0/2 0/2 32 2/2 0/2 0/2 1
Gram 
negative
Acinetobacter 
baumannii
Amikacin 3/9 1/9 5/9 64 5/15 0/15 10/15 64 3/35 2/35 30/35 64 2/17 2/17 13/17 64
Ceftazidime 1/9 2/9 6/9 64 2/15 1/15 12/15 64 1/35 0/35 34/35 64 0/17 0/17 17/17 64
Ciprofloxacin 3/9 0/9 6/9 4 3/15 0/15 12/15 4 1/35 0/35 34/35 4 0/17 0/17 17/17 4
Colistin 8/9 0/9 1/9 2 15/15 0/15 0/15 1 35/35 0/35 0/35 2 16/17 0/17 1/17 0.5
Gentamicin 5/9 0/9 4/9 16 5/15 5/15 5/15 16 19/35 6/35 10/35 16 5/17 4/17 8/17 16
Imipenem 5/9 2/9 2/9 16 6/15 4/15 5/15 16 1/35 5/35 29/35 16 0/17 4/17 13/17 16
Piperacillin/
Tazobactam
2/9 1/9 6/9 128 4/15 1/15 10/15 128 1/35 1/35 33/35 128 0/17 3/17 14/17 128
Pseudomonas 
aeruginosa
Amikacin 15/29 2/29 12/29 64 18/33 1/33 14/33 64 8/25 0/25 17/25 64 7/11 0/11 4/11 64
Ceftazidime 13/29 2/29 15/29 64 14/33 5/33 14/33 64 4/25 7/25 14/25 64 3/11 1/11 7/11 64
Ciprofloxacin 11/29 0/29 18/29 4 14/33 0/33 19/33 4 8/25 0/25 17/25 4 6/11 0/11 5/11 4
Colistin 29/29 0/29 0/29 2 33/33 0/33 0/33 2 25/25 0/25 0/25 2 11/11 0/11 0/11 2
Imipenem 11/29 14/29 4/29 16 19/33 9/33 5/33 16 10/25 6/25 9/25 16 6/11 4/11 1/11 16
Piperacillin/
Tazobactam
26/29 0/29 3/29 64 26/33 1/33 6/33 128 7/25 11/25 7/25 128 9/11 0/11 2/11 128
Klebsiella 
pneumoniae
Ceftazidime 5/7 0/7 2/7 64 23/34 0/34 11/34 64 14/29 1/29 14/29 64 2/11 0/11 9/11 64
Ciprofloxacin 6/7 0/7 1/7 1 22/34 1/34 11/34 4 13/29 0/29 16/29 4 7/11 0/11 4/11 4
Meropenem 7/7 0/7 0/7 0.25 33/34 0/34 1/34 0.5 21/29 4/29 4/29 8 2/11 1/11 8/11 16
Cefepime 7/7 0/7 0/7 2 23/34 1/34 10/34 64 14/29 7/29 8/29 64 2/11 0/11 9/11 64
Cefoxitin 7/7 0/7 0/7 4 24/34 0/34 10/34 64 11/29 0/29 18/29 64 2/11 0/11 9/11 64
Tobramycin 7/7 0/7 0/7 1 26/34 0/34 8/34 16 12/29 1/29 16/29 16 2/11 2/11 7/11 16
Piperacillin/
Tazobactam
7/7 0/7 0/7 8 26/34 1/34 7/34 128 14/29 2/29 13/29 128 2/11 0/11 9/11 128
Escherichia 
coli
Amikacin 35/35 0/35 0/35 2 57/57 0/57 0/57 2 43/47 4/47 0/47 4 29/30 0/30 1/30 4
Ciprofloxacin 28/35 0/35 7/35 4 54/57 0/57 3/57 0.5 43/47 0/47 4/47 4 21/30 0/30 9/30 4
Piperacillin/
Tazobactam
34/35 0/35 1/35 4 56/57 1/57 0/57 4 43/47 1/47 3/47 8 28/30 1/30 1/30 4
Ceftazidime 33/35 0/35 2/35 2 57/57 0/57 0/57 1 43/47 3/47 1/47 1 25/30 0/30 5/30 2
Cefoxitin 31/35 1/35 3/35 16 56/57 1/57 0/57 4 43/47 4/47 0/47 4 26/30 1/30 3/30 16
Meropenem 34/35 1/35 0/35 0.25 57/57 0/57 0/57 0.25 46/47 0/47 1/47 0.25 30/30 0/30 0/30 2Publish with BioMed Central    and   every 
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Abbreviations: *S = susceptible, **I = intermediate, ***R = resistant, #MIC90 = minimum inhibitory concentration for 90% of the corresponding 
microbial population
Table 4: Data on antimicrobial resistance patterns and respective MIC90 of isolated bacteria. (Continued)